

## 2023 Medicare Part B Step Therapy Drug List

- Step therapy requires a trial of a preferred drug to treat a medical condition before covering other drug therapies.
- The step therapy requirement does not apply to members who have already received treatment with the non-preferred drug within the past 365 days.
- These drugs may also be subject to prior authorization and/or quantity limitations.

Drug Class	Drug Products Requiring Step Therapy
Acromegaly	Sandostatin LAR Depot
	Signifor LAR
	Somavert
Adrenocorticotropic Hormone Analogue	Acthar
	Purified Cortrophin Gel
Alpha-1 Antitrypsin Deficiency	Aralast
	Glassia
	Zemaira
Autoimmune Infused/Infliximab	Avsola
	Inflectra
	Infliximab
	lxifi
	Remicade
	Renflexis
Autoimmune Infused/Other	Actemra
	Arcalyst
	Aria Stelara
	Cimzia
	Entyvio
	llaris
	llumya
	Orencia
	Simponi
	Skyrizi
Bevacizumab	Avastin



Drug Class	Drug Products Requiring Step Therap
Bone Density Regulators	Prolia
	Reclast
	Zoledronic Acid
	Zometa
Botulinum Toxins	Botox
	Myobloc
Chimeric Antigen Receptor Therapy	Abecma
	Breyanzi
	Kymriah
	Tecartus
	Yescarta
Gout Therapy	Krystexxa
Hematologic, Erythropoiesis – Stimulating Agents (ESA)	Epogen
	Mircera
	Procrit
Hematologic, Neutropenia Colony Stimulating Factors – Long Acting	Neulasta syringe
Hematologic, Neutropenia Colony Stimulating Factors – Short Acting	Granix
	Leukine
	Neupogen
Hematologic Angioedema (HAE)	Cinryze
Prophylaxis	Takhzyro
Homozygous Familial Hypercholesterolemia (HoFH)	Evkeeza
Iron Products	Feraheme
	Injectafer
Lipodystrophy	Myalept
Lysosomal Storage Disorders –	Cerezyme
Gaucher Disease	VPRIV
Migrane Therapy	Vyepti
Monoclonal Antibodies – Asthma	Cinqair
	Fasenra
	Nucala
	Xolair
Monoclonal Antibody - Other	Enspryng
	Soliris
	Tepezza
	Uplizna

Drug lists are subject to change and will be updated at least 30 days prior to the effective date. Publish Date: 11/2022 Effective Date: 01/2023



Drug Class	Drug Products Requiring Step Therapy
Monoclonal Antibody – Other	Enspryng
	Soliris
	Tepezza
	Uplizna
Multiple Sclerosis (Infused)	Lemtrada
Osteoarthritis, Viscosupplements – Single Injection	Durolane
	Gel-One
	Supartz
	Supartz FX
Osteoarthritis, Viscosupplements – Multi Injection	Euflexxa
	Gelsyn-3
	Genvisc 850
	Hyalgan
	Hymovis
	Supartz
	Supartz FX
	Trivisc
	Visco-3
Prostate Cancer – Luteinizing Hormons Releasing Hormone (LHRH) Agents	Lupron Depot
	Trelstar
	Zoladex
Pulmonary Arterial Hypertension (PAH)	Remodulin
	Tyvaso
Retinal Disorders Agents	Beovu
	Byooviz
	Cimerli
	Eylea
	Lucentis
	Macugen
	Susvimo
	Vabysmo
	Visudyne
Rituximab	Rituxan
	Rituxan Hycela
	Ruxience
	Truxima
Sickle Cell Therapy	Adakveo



Drug Class	Drug Products Requiring Step Therapy
Systemic Lupus Erythematosus (SLE)	Benlysta
Agent	Saphnelo
Trastuzumab	Herceptin
	Herceptin Hylecta

Drug lists are subject to change and will be updated at least 30 days prior to the effective date.

Publish Date: 11/2022 Effective Date: 01/2023

Highmark Wholecare offers HMO plans with a Medicare Contract. Enrollment in these plans depends on contract renewal.

Highmark Wholecare complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. Highmark Wholecare does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

ATTENTION: If you speak English, language assistance services, free of charge, are available to you. Call 1-800-685-5209 (TTY 711).

ATENCIÓN: Si usted habla español, tenemos servicios de asistencia lingüística disponibles para usted sin costo alguno. Llame al 1-800-685-5209 (TTY 711).

小小贴士:如果您说普通话,欢迎使用免费语言协助服务。请拨 1-800-685-5209 (TTY 711).

Health benefits or health benefit administration may be provided by or through Highmark Wholecare, coverage by Gateway Health Plan, an independent licensee of the Blue Cross Blue Shield Association ("Highmark Wholecare").